Annual report
3583.TEDINET S100W2GJ
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥5.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥5.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥841m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥561m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥814m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥601m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥639m | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥332m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥819m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥600m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥580m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥436m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥469m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥115m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥580m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥436m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥9.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥9.3bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥9.4bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥637m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥338m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥631m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥160m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥165m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥184m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥182m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥562m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥451m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥206m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥13m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥209.05 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.8 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.17 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.6 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,439.07 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,246.2 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,100.85 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,957.25 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,753.19 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 68.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 368 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 343 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 340 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 364 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 350 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥5.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥5.0bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥5.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥513m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥341m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥524m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥363m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥492m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥619m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥246m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥529m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥363m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥388m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥260m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥368m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥440m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥190m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.7bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥8.7bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥8.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.3bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.1bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥139.8 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥93.53 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.59 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159.25 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.67 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥33 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,036.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,915.08 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,843.5 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,736.4 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,580.8 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 64.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,092,623 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,092,623 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 125 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 129 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 130 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 132 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 130 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥343m |
| Medical Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥48m |
| Medical Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥66m |
| Medical Productsreportable segment | employees | at 2025-03-31 | 48 pure |
| Medical Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Medical Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| Medical Productsreportable segment | segment assets | at 2025-03-31 | ¥1.5bn |
| Medical Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥124m |
| Technological Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥123m |
| Technological Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥213m |
| Technological Productsreportable segment | employees | at 2025-03-31 | 309 pure |
| Technological Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Technological Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Technological Productsreportable segment | segment assets | at 2025-03-31 | ¥5.9bn |
| Technological Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥171m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥279m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| —segment total | segment assets | at 2025-03-31 | ¥7.4bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥27m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥8m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥861,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥861,000 |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥331m |
| Medical Productsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥48m |
| Medical Productsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥54m |
| Medical Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥861,000 |
| Medical Productsreportable segment | segment assets | at 2024-03-31 | ¥1.5bn |
| Medical Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥150m |
| Technological Productsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥133m |
| Technological Productsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥213m |
| Technological Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Technological Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Technological Productsreportable segment | segment assets | at 2024-03-31 | ¥5.7bn |
| Technological Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥741m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥181m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥267m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥861,000 |
| —segment total | segment assets | at 2024-03-31 | ¥7.2bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥891m |
| Medical Productsreportable segment | employees | at 2025-03-31 | 16 pure |
| Technological Productsreportable segment | employees | at 2025-03-31 | 98 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,525
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in other investments inv cf | CurrentYearDuration | 3478000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -164645000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -159736000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 300000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 380000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -669988000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -720512000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -61613000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -61287000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -18948000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -14439000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -48000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -145754000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -450598000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -561993000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 13039000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | -5863000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 452478000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -90164000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2388065000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2840544000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2840544000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 2750379000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 3 | |
| Notes receivable trade | Prior1YearInstant | 98130000 | JPY |
| Notes receivable trade | CurrentYearInstant | 145260000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 1071100000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 1152357000 | JPY |
| Write downs of inventories | Prior1YearDuration | 1842000 | JPY |
| Write downs of inventories | CurrentYearDuration | 5380000 | JPY |
| Shipment expenses sga | Prior1YearDuration | 106163000 | JPY |
| Shipment expenses sga | CurrentYearDuration | 112283000 | JPY |
| Advertising expenses sga | Prior1YearDuration | 23978000 | JPY |
| Advertising expenses sga | CurrentYearDuration | 15469000 | JPY |
| Salaries allowances and bonuses sga | Prior1YearDuration | 511724000 | JPY |
| Salaries allowances and bonuses sga | CurrentYearDuration | 525465000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 70144000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 97145000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 22723000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 20076000 | JPY |
| Provision for jesop expense sga | Prior1YearDuration | 17986000 | JPY |
| Provision for jesop expense sga | CurrentYearDuration | 38157000 | JPY |
| Welfare expenses sga | Prior1YearDuration | 91684000 | JPY |
| Welfare expenses sga | CurrentYearDuration | 92840000 | JPY |
| Depreciation sga | Prior1YearDuration | 36818000 | JPY |
| Depreciation sga | CurrentYearDuration | 38052000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 113714000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 139832000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00584-000TechnologicalProductsReportableSegmentsMember | 3796313000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00584-000MedicalProductsReportableSegmentsMember | 1590697000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |